Quality Assessment of Various Brands of Lisinopril Tablets sold in Uyo Metropolis using UV Spectrophotometry
Article Sidebar
Main Article Content
Abstract
Lisinopril is an angiotensin-converting enzyme inhibitor (ACEI) used for the management of hypertension. The danger of use of substandard and/or fake lisinopril tablets for management of hypertension cannot be over-emphasised. It will lead to negative treatment outcomes. This necessitates the quality assessment of the different brands of lisinopril marketed and the provision of simple and cost-effective method of assay that will encourage regular and quick sampling. Ten brands of lisinopril tablets were qualitatively assessed for uniformity of weight, friability, hardness, disintegration and dissolution rate using standard physical methods. Quantitative assay was carried out using spectrophotometric method. The spectrophotometric measurement was done at a wavelength of 340nm. Seven brands met the official requirements for uniformity of weight; eight passed the friability test and the hardness tests. All the brands tested passed the disintegration test while only four brands passed the dissolution test. The calibration curve for reference lisinopril in methanol was linear over a concentration range of 0.00-0.1?g/ml. The variation of absorbance with concentration showed correlation with coefficient of correlation (r) of 0.994 and coefficient of determination (r2) of value 0.985. Seven brands passed the British Pharmacopoeia (BP) requirement for percentage drug content of lisinopril (92.5-105.0%). The assay method used in this study is reliable, simple and cost-effective and can be routinely used to assay lisinopril tablets.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Arauz-Pacheco C, Parrott MA and Raskin P (2002). The treatment of hypertension in adult patients with diabetes. Diabetes care, 25(1), 134-147.
Astra Zeneca (2008). Zestril (Lisinopril). https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019777s054lbl.pdf Retrieved 30/03/2019. Atlas SA (2007). The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. Journal of managed care pharmacy, 13(8 Supp B), 9-20.
British Pharmacopoeia (2008). Monographs on Medicinal and Pharmaceutical Substances. Her Majesty’s Stationery Office, London. 1: 534-537.
British Pharmacopoeia (2015). Lisinopril. British Pharmacopoeia Commission, London, III:757-758. Brown CH (2000). Effect of rofecoxib on the antihypertensive activity of lisinopril. Annals of Pharmacotherapy, 34(12), 1486-1486.
Fogari R, Zoppi A, Carretta R, Veglio F, Salvetti A, and Italian Collaborative Study Group. (2002). Effect of indomethacin on the antihypertensive efficacy of valsartan and lisinopril: a multicentre study. Journal of hypertension, 20(5), 1007-1014.
Gross JL, De Azevedo MJ, Silveiro SP, Canani LH, Caramori ML and Zelmanovitz T (2005). Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes care, 28(1), 164-176.
Hogg RJ, Delucchi A, Sakihara G, Wells TG, Tenney F, Batisky DL, Blumer JL, Vogt BA, Lo MW, Hand E, Panebianco D, Rippley R, Shaw W, Shahinfar S (2007). A multicenter study of the pharmacokinetics of lisinopril in pediatric patients with hypertension. Pediatric Nephrology, 22:695–701.
Igboasoiyi AC, Offor AC, and Egeolu AP (2018). Quality Assessment of Various Brands of Ciprofloxacin Hydrochloride Tablets Sold In Uyo Metropolis. Nigerian Journal of Pharmaceutical and Applied Science Research, 7(2), 89-93.
Jaman M, Chowdhury AA, Rana1 AA, Masum SM, Ferdous T, Rashid MA and Karim MM (2015). In vitro evaluation of Ciprofloxacin Hydrochloride. Bangladesh Journal of Science and Industrial Resources, 50(4), 251-256.
Jantratid E, Janssen, N, Reppas, C. and Dressman, JB (2008). Dissolution Media Simulation Conditions in the Proximal Human Gastrointestinal Tract: An Update. Pharmaceutical Resources, 25: 1663-1676.
Katzung B (2012) Basic and Clinical Pharmacology. New York City, New York, McGraw Hill. pp. 175, 184-185.
Lurbe E, Cifkova R, Cruickshank JK, Dillon MJ, Ferreira I, Invitti C, Kuznetsova T, Laurent S, Mancia G, Morales-Olivas F, Rascher W, Redon J, Schaefer F, Seeman T, Stergiou G, Wühl E, Zanchetti A (2009). Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. Journal of hypertension, 27(9), 1719-1742.
Lüscher TF, Creager MA, Beckman JA, and Cosentino F (2003). Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part II. Circulation, 108(13), 1655-1661.
Mackey TK, and Liang BA (2011). The global counterfeit drug trade: patient safety and public health risks. Journal of pharmaceutical sciences, 100(11), 4571-4579.
Menard J, and Patchett A (2001). Angiotensin-Converting Enzyme Inhibitors-V Lisinopril. Advances in Protein Chemistry, 56, 30-32.
Norman JL, Holmes W L, Bell, WA, and Finks SW (2013). Life-threatening ACE inhibitor-induced angioedema after eleven years on lisinopril. Journal of pharmacy practice, 26(4): 382-388.
Noro E, Yokoyama A, Kobayashi M, Shimada H, Suzuki S, Hosokawa M and Sugawara A (2018). Endogenous Purification of NR4A2 (Nurr1) Identified Poly (ADP-Ribose) Polymerase 1 as a Prime Coregulator in Human Adrenocortical H295R Cells. International Journal of Molecular Sciences, 19(5), 1406.
Olalowo AW, Adegbolagun, OM and Bamino OA (2015). Simple Potentiometry and Phenolphthalein Based Titrimetric Methods of Analysis for Lisinopril Tablet. African Journal of Pharmacy and Pharmacology, 9 (6): 165-172.
Shah VP (2001), Dissolution: a quality control test vs a bioequivalent test. Dissolution Technologies 8(4): 1–2.
Soffer B, Zhang Z, Miller K, Vogt BA, Shahinfar S (2003). A double-blind, placebo-controlled, dose–response study of the effectiveness and safety of lisinopril for children with hypertension. American Journal of Hypertension, 16:795–800.
Ubajaka C F, Obi-Okaro AC, Emelumadu of, Azumarah MN, Ukegbu AU and Ilikannu SO (2016). Factors Associated with Drug Counterfeit in Nigeria: A Twelve Year Review. British Journal of Medicine & Medical Research, 12(4): 1-8, 2016, Article no.BJMMR.21342 ISSN: 2231-0614, NLM ID: 101570965 SCIENCEDOMAIN international www.sciencedomain.org
United States Pharmacopoeia National Formulary USP 37NF 32 (2014). Lisinopril Tablets
Official Monograph, United States Pharmacopeial Convention 12601. Twinbrook, Parkway, Rockville MD 208523, 3:3567
Wikipedia (2019). Lisinopril. https://en.wikipedia.org/wiki/Lisinopril Retrieved 30/03/2019